<DOC>
	<DOCNO>NCT00396071</DOCNO>
	<brief_summary>This mechanistic study evaluate effect vildagliptin glucose-stimulated insulin secretion improve incretin effect patient type 2 diabetes .</brief_summary>
	<brief_title>Efficacy Safety Vildagliptin Compared Placebo Incretin Effect Patients With Type 2 Diabetes Treated With Metformin</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Vildagliptin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Incretins</mesh_term>
	<criteria>Patients type 2 diabetes metformin least 3 month stable dose least 1500 mg daily minimum 4 week Agreement maintain dose metformin throughout study Body mass index ( BMI ) range 2235 kg/m2 HbA1c range 7.0 9.0 % FPG &lt; 200 mg/dl ( 11.1 mmol/L ) Agreement maintain prior diet exercise habit full course study Ability comply study requirement sign informed consent participate study A history type 1 diabetes A history acute metabolic diabetic complication Evidence significant diabetic complication Insulin treatment longer 10 day within past 6 month Treatment oral antidiabetic metformin within 3 month prior visit 1 Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>78 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Type 2 diabetes</keyword>
	<keyword>vildagliptin</keyword>
	<keyword>incretin effect</keyword>
	<keyword>metformin</keyword>
</DOC>